Research programme: antiviral vaccines - Immunotope

Drug Profile

Research programme: antiviral vaccines - Immunotope

Alternative Names: Viral haemorrhagic fever vaccine - Immunotope

Latest Information Update: 24 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunotope
  • Class Dengue vaccines; Viral vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dengue; Hepatitis B; Hepatitis C; HIV infections; Influenza virus infections; Viral haemorrhagic fevers

Most Recent Events

  • 15 Sep 2014 Immunotope and CaPtivate Pharmaceuticals sign license agreement for CaP nanoparticle technology
  • 15 Sep 2014 Preclinical trials in Dengue (Prevention) in USA (unspecified route)
  • 15 Sep 2014 Preclinical trials in Hepatitis B in USA (unspecified route) before September 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top